375 related articles for article (PubMed ID: 23993732)
1. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.
Vassalou H; Stathopoulos E; Fiolitaki G; Koutsopoulos A; Voutsina A; Georgoulias V; Mavroudis D
Lung Cancer; 2013 Nov; 82(2):324-9. PubMed ID: 23993732
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
[TBL] [Abstract][Full Text] [Related]
3. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
5. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
[TBL] [Abstract][Full Text] [Related]
6. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
7. [ERCC1 expression and outcomes of neo-adjuvant chemotherapy in elderly patients with non-small cell lung cancer].
Li GF; Deng SJ; Weng WW; Guo G; Chen N
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Sep; 30(9):2131-3. PubMed ID: 20855270
[TBL] [Abstract][Full Text] [Related]
8. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.
Sodja E; Knez L; Kern I; Ovčariček T; Sadikov A; Cufer T
Eur J Cancer; 2012 Dec; 48(18):3378-85. PubMed ID: 22795264
[TBL] [Abstract][Full Text] [Related]
9. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
[TBL] [Abstract][Full Text] [Related]
10. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
[TBL] [Abstract][Full Text] [Related]
11. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.
Okuda K; Sasaki H; Dumontet C; Kawano O; Yukiue H; Yokoyama T; Yano M; Fujii Y
Lung Cancer; 2008 Oct; 62(1):105-12. PubMed ID: 18395930
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.
Lee GW; Go SI; Cho YJ; Jeong YY; Kim HC; Duk Lee J; Hwang YS; Ko GH; Lee JH; Kim DC; Yang JW; Oh S; Lee JS
J Thorac Oncol; 2012 Mar; 7(3):528-34. PubMed ID: 22258474
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two ERCC1 antibodies as prognostic and predictive biomarkers for early non-small cell lung cancer.
Muley TR; Sianidou M; Thomas M; Bischoff H; Dienemann H; Meister M; Schneider MA; Schnabel PA; Warth A
Anticancer Res; 2014 Jul; 34(7):3707-13. PubMed ID: 24982391
[TBL] [Abstract][Full Text] [Related]
14. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
15. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy.
Lee HW; Choi YW; Han JH; Kim JH; Jung JH; Jeong SH; Kang SY; Choi JH; Oh YT; Park KJ; Hwang SC; Sheen SS
Lung Cancer; 2009 Sep; 65(3):377-82. PubMed ID: 19150580
[TBL] [Abstract][Full Text] [Related]
16. ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy.
Das M; Riess JW; Frankel P; Schwartz E; Bennis R; Hsieh HB; Liu X; Ly JC; Zhou L; Nieva JJ; Wakelee HA; Bruce RH
Lung Cancer; 2012 Aug; 77(2):421-6. PubMed ID: 22555222
[TBL] [Abstract][Full Text] [Related]
17. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
Kang CH; Jang BG; Kim DW; Chung DH; Kim YT; Jheon S; Sung SW; Kim JH
Lung Cancer; 2010 Jun; 68(3):478-83. PubMed ID: 19683826
[TBL] [Abstract][Full Text] [Related]
18. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
Olaussen KA; Mountzios G; Soria JC
Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
[TBL] [Abstract][Full Text] [Related]
19. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ
Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869
[TBL] [Abstract][Full Text] [Related]
20. ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer.
Muallem MZ; Braicu I; Nassir M; Richter R; Sehouli J; Arsenic R
Anticancer Res; 2014 Jan; 34(1):393-9. PubMed ID: 24403493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]